Home › Bleeding › NCT06582810

Lidocaine Infusion Treatment for Subarachnoid Hemorrhage Headaches

Lidocaine Infusion As A Treatment Modality For Headache Following Non-Traumatic Subarachnoid Hemorrhage: A Prospective, Single-Center, Observational Cohort Study

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Patients \> 18 years;
* Have a favorable neurological status defined as Hunt and Hess score ≤ 3 (as it accounts for patient awareness);
* Can communicate numeric pain scores;
* Are diagnosed with non-traumatic subarachnoid hemorrhage

Exclusion Criteria:

* The patient is diagnosed with traumatic subarachnoid hemorrhage;
* If the patient is \< 18 years of age;
* If numeric pain scores could not be captured for \> 3 days of hospitalization;
* If the patient had a prior aneurysm;
* Chronic pain not associated with non-traumatic subarachnoid hemorrhage diagnosis;
* A disability before the stroke (\> 2 on modified Rankin Scale score);
* A Hunt and Hess score \> 3;
* Contraindications to lidocaine (significant cardiac disease, arrhythmia, seizures, previous allergic reaction to lidocaine

About the study

The goal of this observational study is to evaluate intravenous lidocaine efficacy and safety in treating headache following non-traumatic subarachnoid hemorrhage. Through this prospective analysis, the investigators hope to:

1. show that intravenous lidocaine infusion causes a clinically significant reduction in pain scores in patients with moderate/severe headache pain following non-traumatic subarachnoid hemorrhage; 2. show that intravenous lidocaine infusion is safe in treating headache following non-traumatic subarachnoid hemorrhage; 3. and report vasospasm prevalence in the cohort.

Participants will receive lidocaine infusion as treatment for non-traumatic subarachnoid hemorrhage headache and provide pain scores (on a numeric pain scale) every two hours the patients are awake for a maximum of seven days. Monitoring for vasospasm will occur as part of the patients regular medical care.

Sponsor: University of Kansas Medical Center · Participants: 20 · Started: Jan 31, 2025

Contact the study team

• William L Krogman, MS · Phone: 316-268-6156

Official record on ClinicalTrials.gov — NCT06582810

Locations in the U.S.

Conditions

• Bleeding
• Headache

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.